FDA Policy Power Challenged In House Questions On Untitled Letters
This article was originally published in The Tan Sheet
Executive Summary
Oversight and Investigations Subcommittee Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours. The Energy and Commerce Committee examines whether FDA use of untitled letters is “fair, effective and efficient in gaining compliance,” he says.
You may also be interested in...
US FDA Considers Making More Guidance Final Without Public Comment
Increased use of the ‘immediate implementation’ provision in the agency’s Good Guidance Practices could help reduce stakeholder uncertainty.
US FDA Considers Making More Guidance Final Without Public Comment
Increased use of the ‘immediate implementation’ provision in the agency’s Good Guidance Practices could help reduce stakeholder uncertainty.
FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks
FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.